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ABSTRACT
Results of a randomized prospective study are reported in which m itom ycin C, Tice bacillus 
Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients w ith  primary or recur­
rent pTa and pTl bladder tumors, including carcinoma in situ. The followup (or tim e in  study) 
varied from 2 to 81 months (mean 36 months). After complete transurethral resection of all 
visible tumors the patients were treated with 30 mg. m itom ycin C once a w eek for 4 consecutive 
weeks and thereafter every month for a total of 6 m onths, and 5 X 108 colony-forming units Tice 
BCG or RIVM-BCG once a week for 6 consecutive w eeks. For papillary tum ors m itom ycin C and 
RIVM-BCG treatments were equally effective (p = 0.53), and m itom ycin C w as more effective 
than Tice BCG therapy (p = 0.01).
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In pTa and pTl bladder cancer intravesical chemotherapy 
and immunotherapy are used as adjuvant treatment after 
transurethral resection. Both therapies can reduce the high 
rate of recurrences in papillary tumors as well as eradicate 
carcinoma in situ.1^ 5 Response rates of different studies com­
paring chemotherapeutic agents versus bacillus Calmette- 
Guerin (BCG) after transurethral resection in patients with 
pTa, pTl and carcinoma in situ bladder tumors suggest that 
BCG is superior to thiotepa, doxorubicin or mitomycin C.4,6 
Mitomycin C was selected as a chemotherapeutic agent in 
our study because of its proved efficacy in regard to preven­
tion of tumor recurrence and high response rate in patients 
with carcinoma in situ.7-9
In 1988 we reported the results of a prospective trial in 
which mitomycin C was compared with RIVM-BCG, and no 
statistically significant differences in toxicity and efficacy 
were noted between the 2 arms.10 Because of the lack of 
superiority of RIVM-BCG over mitomycin C, the efficacy of 
RIVM-BCG was questioned. BCG is a biological product, 
consisting of living bacteria, subcellular debris and adjuvant 
compounds. Considerable differences in the various strains 
and even lots of the same strain can be present.11 Most of the 
BCG strains, for example Tice BCG, are grown as a surface 
pellicle, ground in a ball mill, resuspended and freeze-dried. 
However, RIVM-BCG is grown in a homogeneously dispersed 
culture and lyophilized in a solution containing glucose and 
polysorbate 80.
It has been suggested that those strains with the best 
ability to bind to fibronectin could be the strains with the 
most potent antitumor efficacy. The glycoprotein fibronectin 
has an important role in the attachment of BCG to the 
bladder wall, which has been demonstrated in mice.12 At 
least in the mouse model BCG strains grown as a surface 
culture (Tice) showed a better attachment to the bladder wall 
than homogeneously dispersed cultured BCG (RIVM).13 
These observations led to the necessity to compare the 2 
different BCG strains to each other and to a well known 
chemotherapeutic drug.
The first objective of our 3-arm prospective, controlled and
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randomized trial was to compare the efficacy of mitomycin C 
chemotherapy with that of BCG immunotherapy, using 2 
different substrains in patients with primary or recurrent 
pTa, pTl and carcinoma in situ bladder tumors. The param­
eters compared were duration of disease-free interval and the 
rate of progression to a higher stage (T category) of disease. 
The second objective was to compare the incidence and se­
verity of side effects of the treatments. Primary end point of 
the study was the time to recurrence of bladder tumors, 
which was considered treatment failure.
M A TER IA LS A N D  M E T H O D S
From April 1987 to December 1990, 469 patients entered 
the study from 27 institutions of the Dutch Southeast Coop­
erative Urological Group. All patients had histologically 
proved papillary pTa-pTl transitional cell carcinoma of the 
bladder with or without concomitant or primary carcinoma in 
situ. Pathological classification was done according to the 
tumor, node and metastasis system ,14 and grading was done 
according to the method of Koss.15 The highest stage and 
grade of all tumor specimens in individual cases were used to 
characterize each case. All specimens of tumor and bladder 
biopsies were reviewed by a single pathologist. The toxicity, 
local and systemic side effects, has been reported else­
where.16 Briefly, side effects were classified as local, systemic 
or allergic. Local toxicity was defined as the occurrence of 
culture proved bacterial cystitis (not BCG related), drug- 
induced cystitis (mitomycin C or BCG related) or other local 
side effects, such as hematuria, prostatitis and epididymitis. 
The severity of side effects was scored by classifying them as 
requiring no delay, delay or cessation of instillation therapy.
Treatment. Intravesical chemotherapy consisted of 30 mg. 
mitomycin C in 50 ml. saline instilled once a week for 1 
month (week 1 to 4) and thereafter once a month for a total 
of 6 months. If superficial tumor recurred or carcinoma in 
situ persisted at 3 months the treatment schedule was not 
changed after complete transurethral resection (or biopsy), 
and if disease recurred or persisted after 6 months 3 addi­
tional monthly mitomycin C instillations were given.
Intravesical immunotherapy was performed with Tice
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BCG or with RIVM-BCG. BCG was administered (5 X 10s 
colony-forming units in 50 ml. saline) once a week for 6 
consecutive weeks. If superficial tumor recurred or carci­
noma in situ persisted at 3 or 6 months a second 6-week 
course with BCG instillations was given after complete trans­
urethral resection or biopsy. In all other cases of recurrences, 
irrespective of the treatment arm, the patient went off study 
and treatment was left to the discretion of the urologist.
Followup and treatment response. Followup cystoscopy was 
performed at 3-month intervals during the first 2 years after 
transurethral resection, and thereafter at 4 and 6-month 
intervals. Cytology was done at each cystoscopy. For papil­
lary tumors the efficacy of the therapy was evaluated by 
determining the disease-free period after randomization. The 
response to therapy in patients with carcinoma in situ was 
scored as no response or a complete response. Complete re­
sponse was defined as the complete disappearance of carci­
noma in situ, documented by normal urine cytology, cysto- 
scopic examination and bladder biopsies.
Statistical analysis. To detect a difference of 50% in the 
median duration of the disease-free interval between mito­
mycin C and the best (smallest hazard rate) of the BCG 
treatments (assuming the time to recurrence follows an ex­
ponential distribution), 90 eligible and evaluable patients 
followed until recurrence were required in each treatment 
arm (error probabilities a = 0.05 and ß = 0.20). Assuming 
that 65% of the patients will have at least 1 recurrence 
during the study, 138 evaluable patients per treatment arm 
were needed, for a total of 414 evaluable patients. For ran­
domization the restricted block wise (block size 6 equals 3 
treatments times 2 patients per treatment) randomization 
was used. Estimation of the cumulative distribution of the 
disease-free interval was performed by the Kaplan and Meier 
method for each of the 3 treatment groups and for subgroups. 
Differences in the distribution of the disease-free interval 
were tested with the log rank test. For testing of the differ-
Table 1. Tumor characteristics of evaluable patients and
allocation to treatment
No. 
Mitomycin C
No. 
Tice BCG
No.
RIVM-BCG
Total 
No, (%)
Sfcage pTa;
Grade 1 24 28 32 84
Grade 2 55 48 54 157
Grade 3 4 5 4 13
Total 254 (65.6)
Stage pTl:
Grade 1 -- — -- -- -
Grade 2 31 18 23 72
Grade 3 22 IS 21 61
Total 133 (34.4)
Primary 104 87 108 299
Recurrent 32 30 26 88
Total papillary tumors 136 117 134 387
Ca in situ 12 23 15 50
Totals 148 140 149 437
ence between sample percentages the chi-square test was 
used. All statistical computations were done using statistical 
analysis system procedures.
R ESU LTS
Eligibility. Of the 469 patients who entered the study 17 (6%) 
were ineligible because of no malignancy after pathological re­
view (9), tumor stage greater than pTl after pathological review 
(6) and prior intravesical chemotherapy (2), and they were 
excluded from subsequent analysis. Another 15 patients (3%) 
were also excluded from subsequent analysis because of first 
instillation more than 4 weeks after transurethral resection 
(4), no instillations started due to hematuria (2), refusal (2), 
medication problems (2), death (1), myocardial infarction (1) 
before the instillation procedure and other reasons (3). Ulti­
mately 437 patients were eligible for analysis. Followup 
(time in study) of these patients varied from 2 to 81 months 
(mean 36 months).
Patient and tumor characteristics. Tumor characteristics 
were equally distributed among the 3 treatment arms (table 
1). Ofthe 437 eligible patients 50 had carcinoma in situ, 254 
had pTa tumors and 133 had pTl tumors (table 1). Of the 
patients with carcinoma in situ 12 received mitomycin C, 23 
Tice BCG and 15 RIVM-BCG. After complete transurethral 
resection patients with pTa or pTl papillary tumors were 
treated with mitomycin C (136), Tice BCG (117) and RIVM- 
BCG (134). Of the patients with carcinoma in situ 25 had 
pure flat multifocal carcinoma in situ and 25 also had papil­
lary tumors (concomitant carcinoma in situ). Of ail patients 
84 had pTa grade 1 tumors, including 43 with a solitary 
tumor and 41 with multiple (2 to 8) tumors.
Off study patients. A total of 230 patients (74 treated with 
mitomycin C, 76 Tice BCG and 80 RIVM-BCG) went off study 
because of recurrence at or after 9 months (122), protocol 
violation (36), progression in tumor stage to T2 or higher (23), 
adverse effects (14), intercurrent death (10), treatment re­
fusal (7), lost to followup (3) and other reasons (15). A de­
tailed differentiation of reasons for off study is shown in table 
2.
jEfficacy of treatment. For stages pTa and pTl papillary 
tumors the time to first recurrence was recorded. Recurrence 
was noted during the study in 58 of 136 patients (43%) 
treated with mitomycin C, 75 of 117 (64%) treated with Tice 
BCG and 62 of 134 (46%) treated with RIVM-BCG. The 
estimated percentages of disease-free patients in the 3 treat­
ment arms are shown in table 3. The analysis of efficacy in 
the patients with papillary tumors shows a statistically sig­
nificant difference among the treatment arms (p = 0.04). The 
mitomycin C and RIVM-BCG treatments were equally effec­
tive (p = 0.53) but mitomycin C was more effective than Tice 
BCG (p = 0,01, see figure). For carcinoma in situ the com­
plete response was analyzed as parameter of efficacy. In all 
50 patients with carcinoma in situ the complete response was 
68% for a duration of 2 to 49 months (mean 19). Complete 
response was 67% (8 of 12 patients) for mitomycin C, 74% (17 
of 23) for Tice BCG and 60% (9 of 15) for RIVM-BCG. These
Table 2. Reasons off study differentiated by treatment arm
Mitomycin G Tice BCG RIVM-BCG Total
NoCft 
In Situ
Ca 
In Situ
No Ca Ca 
In Situ In Situ
No Ca 
In Situ
Ca 
In Situ
NoCa 
In Situ
Ca 
In Situ
Recurrences 31 3 39 7 36 6 106 16
Protocol violation 14 6 8 1 6 1 28 8
Progression 8 — 5 2 4 4 17 6
Adverse effect 3 — 5 2 4 12 2
Death 2 — 1 2 4 1 7 3
Refusal 1 — 1 — 5 7
Lost to followup 1 — 1 — 1 3
Other _5 — _2 — 6 2 13 2
Totals 65 9 62 14 66 14 193 37
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T able 3. Treatment efficacy defined as percentage o f patients
free of tumor at 5 years o f followup
Yrs. Mitomycin C Tice BCG RIVM-BCG
1 73 ± 4 66 ± 5 70 ± 4
2 61 ± 5 53 ± 5 61 ± 5
3 59 ± 5 42 ± 5 55 ± 5
4 57 ± 5 36 ± 5 54 ± 5
5 57 ± 5 36 ± 5 54 ± 5*
Per cent disease-free with standard error and all papillary tumors. 
* No failures seen after 4 years.
results do not allow any conclusion to be drawn because the 
numbers of patients randomized are too small.
Progression in tumor stage. Progression in stage (pT2 or 
higher) at recurrence (patients who went off study) was ob­
served in 8 (6%) of the mitomycin C group, 7 (5%) of the Tice 
BCG group and 8 (6%) treated with the RIVM-BCG,
Toxicity. The number and severity of adverse effects were 
recorded during the instillation period (6 months for mito­
mycin C, 6 weeks for BCG) and are listed in table 4. Between 
the BCG groups no statistical difference in number and se­
verity was found. Drug-induced cystitis, other local side ef­
fects and systemic side effects were significantly less fre­
quent in the mitomycin C group. Three of 148 patients (2%) 
had to stop mitomycin C treatment, 5 of 140 (4%) stopped 
Tice BCG and 11 of 149 (7%) stopped RIVM-BCG. No life
threatening adverse effects or treatment related deaths were 
recorded.
DISCUSSION
The primary objective in this study was to compare the 
efficacy of mitomycin C chemotherapy with that of BCG 
immunotherapy, using 2 different strains, in patients with 
pTa, pTl and carcinoma in situ bladder cancer. The efficacy 
in patients with papillary tumors was related to the percent­
age disease-free period after transurethral resection of all 
visible tumors. When all patients with papillary tumors 
(grades 1, 2 and 3, and stages pTa and pTl) were analyzed
together a statistically significant difference was seen in 
efficacy among the 3 treatment schemes in favor of mitomy­
cin C and RIVM-BCG treated patients compared to Tice BCG 
treated patients.
Because of statistical reasons, definitive results of this 
study should be withheld until at least 50% of the patients in. 
each of the 3 arms have shown recurrent tumor. However, 
after 3 years of followup only the Tice BCG group has a slight 
decrease from 42% disease-free at 3 years to 36% after 4 and 
5 years, respectively (table 2). The disease-free percentage 
for mitomycin C decreases only from 59% at 3 years to 57% at 
5 years and for RIVM-BCG it decreases only from 55 to 54% 
at 3 and 5 years, respectively. Since in superficial bladder 
studies most recurrences are observed in the first 2 years after 
randomization, it is hard to estimate how many years are 
needed to obtain less than 50% disease-free in all 3 arms (see 
figure).
Only a few studies have presented a 5-year followup of 
patients with superficial bladder cancer treated with mito­
mycin C or BCG. Lamm reported the estimated 5-year recur­
rence rates of 78% for mitomycin C treated patients and 48% 
for BCG treated patients.17 This means that 22% of patients 
treated with mitomycin C and 52% of those treated with BCG 
were tumor-free after 5 years. Our results are comparable for 
BCG patients. The percentage of patients free of tumor after 
5 years was 54% of RIVM-BCG, 36% of Tice BCG and 57% of 
mitomycin C treated patients. Although intravesical chemo­
therapy delays the time to first recurrence, it is unknown 
whether chemotherapy influences progression and survival. 
Recent studies suggest that the time to progression is pro­
longed with intravesical immunotherapy in patients with 
superficial bladder cancer.18,19 The progression rate in our 
study was low at 6%, 5% and 4% for mitomycin C, Tice BCG 
and RIVM-BCG, respectively. Our data do not indicate that 
the progression rate to muscle-invasive disease was different 
in any of the treatment arms, which may explain the rela­
tively low number of grade 3 and T1 tumors as well as the low 
number of carcinoma in situ patients. Mosj: of the patients 
had intermediate risk tumors. Tumor grade did not signifi-
% o f  d i s e a s e - f r e e pTa and pT1 tumours
t i m e  i n  y e a r s
TRMT ----------  TICE ( tm) BCG ----------  B C G - R I V M --------- M i t o m y c i n - C
Kaplan-Meier plots of percentage of patients with papillary tumors pTa and pTl, grades 1 to 3 transitional cell cancer free of tumor after 
transurethral resection and treatment with mitomycin C (dashed line), Tice BCG (solid line) and RIVM-BCG (dotted line). Log rank test, 
p =  0.04.
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T ab le  4. Side effects during instillation period
No. 
Mitomycin C
No. 
Tice BCG
No.
RIVM-BCG
Total 
No. (%)
Bacterial cystitis 
(p = 0.20):
No 121 102 115 338
Yes, without delay 25 26 24 75
Yes, with delay 1 11 10 22
Stop treatment 1 1 — 2
Total No. yes (%) 27 (18.2) 38 (27.1) 34 (22.8) 99 (22.7)
Drug-induced cystitis 
(p = 0.009):
No 122 98 101 321
Yes, without delay 25 40 45 110
Yes, with delay 1 1 2 4
Stop treatment — 1 1 2
Total No. yes (%) 26 (17.6) 42 (30.0) 48 (32.2) 116 (26.5)
Allergic reaction 
(p = 0.30):
No 141 137 146 424
Yes, without delay 4 2 2 8
Yes, with delay 1 1 1 3
Stop treatment 2 — — 2
Total No. yes (%) 7 (4.7) 3 (2.1) 3 (2.0)
i
13 (3.0)
Other local aide effects 
(p = 0.004):
No 141 117 127 385
Yes, without delay 7 23 20 50
Yes, with delay — — 2 2
Total No. yes {%) 7 (4.7) 23 (16.4) 22 (14.8) 52 (11.9)
Systemic side effects 
(p < 0.001):
No 142 102 122 366
Yes, without delay 6 32 24 62
Yea, with delay — 3 1 4
Stop treatment — 3 2 5
Total No. yes (%) 6 (4.1) 38 (27.1) 27(18.1) 71 (16.3)
cantly influence the time to treatment failure for any of the 
groups.
Our study included 84 patients with pTa grade 1 tumors. 
These low stage, low grade tumors have a low risk for recur­
rence or progression if they are solitary. Of the 84 pTa grade 
1 cases 43 had a solitary tumor and 41 had multiple primary 
or recurrent tumors. However, multiple pTa grade 1 tumors 
have an intermediate risk for recurrences, which indicates 
that in our study only 43 of all eligible patients (9.8%) had a 
low risk for recurrence or progression. This also means that 
90.2% of the patients may have had at least potential benefit 
of adjuvant intravesical therapy after transurethral resec­
tion. Therefore, the significance of the results is not particu­
larly diluted by inclusion of the 10% of patients at low risk.
Comparing a 6-week BCG schedule to 6 months of mito­
mycin C therapy, our data do not provide evidence that BCG 
offers better response in the treatment of patients with pTa 
and pTl bladder tumors than mitomycin C. In patients with 
primary or concomitant carcinoma in situ, immunotherapy 
with BCG also was not superior to chemotherapy with mito­
mycin C. However, the efficacy results in patients with car­
cinoma in situ do not allow any conclusion to be drawn 
because too few patients with carcinoma in situ were entered 
in this study.
This study does not address the issue of whether a 6-week 
course of BCG is less effective than BCG maintenance ther­
apy. However, it remains useful to look at the response rates 
in different studies in which 6-week courses, repeated 6 -week 
courses or maintenance therapy has been used.4,19*20 Com­
parisons with other reported studies must be interpreted 
with caution because of multiple variable factors, such as 
different doses, instillation schedules, selected patient 
groups and so forth.
In Southwest Oncology Group study 8795 a randomized 
comparison of Tice BCG and mitomycin C was performed in 
469 patients.21 Of 377 evaluable patients 37 tumor recur­
rences were documented in the 190 BCG treated patients 
(19.4%) versus 61 recurrences in the 187 mitomycin C 
treated patients (32.6%) (p = 0.0052). The highly significant 
advantage of BCG over mitomycin C prompted early closure 
ofthe trial However, in the Southwest Oncology Group trial 
at least 3 major differences can be noted compared to our 
study. In study 8795 only patients with rapidly recurring 
tumors (high risk) were enrolled, they were treated by main­
tenance therapy and the 20 mg. dose of mitomycin C was low,
Mr. Wim Lemmens assisted with the data processing, Dr. 
Ewout Schaafsma reviewed the histological slides and Dr. Rinie 
van Gils Gielen evaluated the carcinoma in situ patients.
REFEREN CES
1. Witjes, J. A., van der Meijden, A. P. and Debruyne, F. M.: Use of
intravesical bacillus Calmette-Guerin in the treatment of su­
perficial transitional cell carcinoma of the bladder: an over­
view. Urol. Int., 45: 129, 1990.
2. Lamm, D. L., Thor, D. E., Stogdill, V. D. and Radwin, H. M.:
Bladder cancer immunotherapy. J , Urol., 128: 931, 1982.
3. Pinsky, C. M,, Camacho, F. J„ Kerr, D., Braun, D. W., Jr.,
Whitmore, W. F., Jr. and Oettgen, H. F.: Treatment of super­
ficial bladder cancer with intravesical BCG. In: Immuno­
therapy of Human Cancer. Edited by W. D. Terry and S. A. 
Rosenberg. New York: Elsevier-North Holland, sect. 7, pp. 
309-312, 1982.
4. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J, E.,
Scardino, P., Grossman, H. B., Stanisic, T, H., Smith, J. A., Jr., 
Sullivan, J., Sarosdy, M. F., Crissman, J. D. and Coltman,
C. A,: A randomized trial of intravesical doxorubicin and im­
munotherapy with bacille Calmette-Guerin for transitional­
cell carcinoma of the bladder. New Engl. J. Med., 325: 1205, 
1991.
5. De Jager, R., Guinan, P., Lamm, D., Khanna, O., Brosman, S.,
DeKernion, J., Williams, R., Richardson, C., Muenz, L., 
Reitsma, D. and Hanna, M. G., Jr.: Long-term complete remis­
sion in bladder carcinoma in situ with intravesical Tice bacil­
lus Calmette Guerin. Overview analysis of six phase II clinical 
trials. Urology, 38: 507, 1991.
6. Herr, H. W.: Intravesical therapy. A critical overview. Urol. Clin,
N. Amer., 14: 399, 1987.
7. Huland, H., Otto, U., Droese, M, and Klöppel, G.: Long-term
mitomycin C instillation after transurethral resection of su­
perficial bladder carcinoma: influence on recurrence, progres­
sion and survival. J. Urol., 132: 27, 1984.
8. Bracken, R. B., Johnson, D. E., Von Eschenbach, A. C., Swanson,
D. A., De Furia, D, and Crooke, S.: Role of intravesical mito­
mycin C in management of superficial bladder tumors, Urol­
ogy, 16: 11, 1980.
9. Soloway, M. S.: Evaluation and management of patients with
superficial bladder cancer, Urol. Clin. N. Amer., 14: 771,1987.
10. DeBruyne, F. M., van der Meijden, A. P., Geboers, A. D.,
Franssen, M. P., van Leeuwen, M. J., Steerenberg, P. A,, de 
Jong, W. H. and Ruitenberg, J. J.: BCG (RIVM) versus mito­
mycin intravesical therapy in superficial bladder cancer. First 
results of randomized prospective trial. Urology, suppl., 31:20, 
1988.
11. Kelley, D. R., Ratliff, T. L., Catalona, W. J., Shapiro, A., Lage,
J. M., Bauer, W. C., Haaff, E, O. and Dresner, S. M.: Intraves­
ical bacillus Calmette-Guérin therapy for supei'ficial bladder 
cancer: effect of bacillus Calmette-Guérin viability on treat­
ment results, J. Urol., 134: 48, 1985.
12. Ratliff, T. L., Palmer, J. O., McGarr, J. A. and Brown, E, J.: Intra­
vesical Bacillus Calmette-Guerin therapy for murine bladder 
tumors: initiation of response by fibronectin-mediated attach­
ment of Bacillus Calmette-Guerin. Cancer Res., 47:1762,1987.
13. Ratliff, T. L., Kavoussi, L. R. and Catalona, W. J.: Role of fi­
bronectin in intravesical BCG therapy for superficial bladder 
cancer. J. Urol., 139: 410, 1988.
14. Hermanek, P. and Sobin, L, H.: TNM Classification of Malignant
Tumours, 4th ed. Heidelberg: Springer-Verlag, 1987. 
lfî. Koss, L. G.: Tumors of the urinary bladder. Atlas of Tumor 
Pathology, 2nd series. Washington, D. C.: Armed Forces Insti­
tute of Pathology, fasc. 11, 1975.
16. Witjes, J. A , van der Meÿden, A, P. M., Witjes, W. P. J., 
Doesburg, W., Schaafsma, H. E. and Debruyne, F. M, J.: A
TREATMENT OF PAPILLARY CARCINOMA AND CARCINOMA IN SITU  OF BLADDER 933
randomized prospective study comparing intravesical instilla­
tions of Mitomycin-C, BCG-Tice and BCG-RIVM in pTa-pTl 
tumors and primary carcinoma in situ of the urinary bladder. 
Eur. J. Cancer, 29A: 1672, 1993.
17. Lamm, D. L.: Long-term results of intravesical therapy for su­
perficial bladder cancer. Urol, Clin. N. Amer., 19: 573, 1992,
18. Reitsma, D. J., Guinan, P., Lamm, D. L., Khanna, O. P., Brosma,
S. A., DeKernion, J. B., Williams, R. D., Simpson, G. and 
Hanna, M. G., Jr.: Long-term effect of intravesical bacillus 
Calmette-Guerin (BCG) Tice strain on flat carcinoma in situ of 
the bladder. Prog. Clin. Biol. Res., 310: 171, 1989.
19. Badalament, R. A., Herr, H. W., Wong, G. Y., Gnecco, C., Pinsky,
C. M., Whitmore, W. F., Jr., Fair, W. R. and Oettgen, H. F.: A 
prospective randomized trial of maintenance versus nonmain­
tenance intravesical bacillus Calmette-Guérin therapy of su­
perficial bladder cancer. J. Clin. Oncol., 5: 441, 1987.
20. Hudson, M. A., Ratliff, T. L., Gillen, D. P., Haaff, E. 0., Dresner,
S. M. and Catalona, W. J,; Single course versus maintenance 
bacillus Calmette-Guérin therapy for superficial bladder tu­
mors: a prospective, randomized trial. J. Urol., 138:295,1987.
21. Lamm, D. L., Crawford, E. D., Blumenstein, B., Crissman, J.,
deVere White, R., Wolf, M., Lowe, B., Sarosdy, M., 
Schellhammer, P., Sagalowsky, A., Smith, J., Grossman, H. B.> 
Flanigan, R., Moon, T., Brendler, C. and Coltman, C.: SWOG 
8795: a randomized comparison of bacillus Calmette Guerin 
and mitomycin C prophylaxis in stage Ta and T1 transitional 
cell carcinoma of the bladder. J. Urol., part 2, 149: 282A, 
abstract 275, 1993.
EDITORIAL COMMENT
The primary goal of intracavitary therapy is to eradicate existing 
disease (treatment) and/or to prevent recurrent disease (prophylax­
is). Few contemporary trials evaluate the former subset, since it is 
believed to be unethical to leave a “marker lesion” to evaluate the 
definitive effect of intravesical therapy. The exception to this is 
carcinoma in situ, which is often diffuse and not amenable to com­
plete surgical resection. Therefore, clinical trials such as that re­
ported by the Dutch Southeast Cooperative Urological Group, which 
include carcinoma in situ should evaluate and report each compo­
nent, that is one as treatment of carcinoma in situ and the other as 
prophylaxis.
The goal of prophylaxis is obvious, namely to prevent recurrence 
and progression of the disease. Ample evidence exists that intraves­
ical chemotherapy and immunotherapy are capable of preventing 
recurrences. Studies suggest that there exists a salutary effect in 
reducing the progression rate (reference 17 in article). However, no 
study has convincingly demonstrated that intracavitary therapy im­
proves survival, although a recent Southwest Oncology Group pro­
tocol would suggest this. Therefore, the primary end point examined 
in a superficial bladder trial is time to recurrence, "which is influ­
enced by the risk of recurrence and the length of followup. The 
inclusion of patients at significant risk for recurrence helps to assure 
the validity of any comparisons. For example, a trial could be under­
taken, which shows that intravesical BCG shows no advantage over 
an oral placebo. Obviously all that would need to be done would be to 
include patients at low risk of recurrence and progression, namely 
those with the first TA grade 1 solitary tumor. In order to compare 
patients with substantial risk of recurrence patients should have 
histologically proved, completely resected stage TA or T1 transi­
tional cell carcinoma and be judged to be at increased risk for tumor 
recurrence by virtue of 2 occurrences of the tumor within 56 weeks, 
stage T1 tumor within 16 weeks of registration, or 3 or more tumors 
presenting simultaneously within 16 weeks. Patients presenting 
with stages TA and T1 with concurrent carcinoma in situ are also 
eligible and, as mentioned, are considered in the treatment rather 
than prophylaxis group. Therefore, the target population represents 
a group who have not received the drug being evaluated and have at 
least an 80 to 90% chance of recurrence within 12 to 24 months. 
These are the criteria used in Southwest Oncology Group studies.
The current clinical trial evaluates 2 different strains of the im- 
munotherapeutic agent BCG and compares them to a widely ac­
cepted intravesical chemotherapeutic drug, mitomycin C. Patients 
entered were those deemed at risk of recurrence with completely 
resected papillary pTA and pTl transitional cell carcinoma of the 
bladder with or without concurrent carcinoma in situ. Primary car­
cinoma in situ was also studied. The statistical design is such to 
detect a 50% difference in the median duration of disease-free inter­
val between mitomycin C and the 2 intracavitary immunotherapy 
BCG treatment arms. Patients in the study needed at least a 65% 
risk of recurrence during the study, and the study is powered at 80% 
chance of detecting the aforementioned differences. The authors 
state that their study only includes 43 patients (9.8%) who were at 
low risk for recurrence or progression. A total of 254 cases (65.6%) 
was pTA grades 1 to 3 but 84 were pTA grade 1, which I would 
consider a low risk for recurrence. Of the patients 34% had lamina 
propria invasion (pTl grades 1 to 3). However, only 88 of the 387 
papillary tumors were recurrent. Unfortunately, only 50 patients 
were accrued who had carcinoma in situ, including 12 in the mito­
mycin, 23 in the Tice BCG and 15 in the RIVM-BCG arm. These are 
too few patients to draw any conclusions regarding the efficacy of any 
of these drugs in the treatment of carcinoma in situ.
Treatment schedules vary considerably from that which is com­
monly practiced in the United States. Thirty mg. mitomycin C and 50 
ml. saline were instilled once a week for 4 weeks and then once a 
month for 6 months. In patients who had a recurrence at 3 months 
the tumor was resected and the treatment was continued. However, 
if a tumor was noted at 6 months 3 additional monthly treatments 
were given. In comparing the results to Southwest Oncology Group 
trials and most other large intravesical trials in the United States, it 
is important to remember that cases with tumors at 3 or 6 months 
are considered treatment failures (reference 4 in article).1 In this 
study the envelope of treatment was extended and the case was not 
considered a failure at 3 or 6 months. The administration of both 
strains of BCG was accomplished on a 6-week basis, followed by 
another 6-week course at 3 and 6 months if recurrence was noted. 
This initial 6-week treatment was standard at the institution of the 
study but a recent Southwest Oncology Group protocol would favor 
maintenance therapy for 6 weeks.1 There were no life threatening 
toxicities in any of the treatment arms, In Southwest Oncology 
Group studies we have reported 2 deaths from BCG.1 The authors 
report a decreased incidence of local side effects as well as systemic 
effects in the mitomycin C arm.
In a recently completed Southwest Oncology Group trial compar­
ing Tice BCG to mitomycin C, BCG significantly improved time to 
recurrence (reference 21 in article). However, the dose of mitomycin 
C as well as the administration schedule are different in this Dutch 
trial. The current study emphasizes the continued role of intravesi­
cal chemotherapy, particularly with mitomycin C, to prevent recur­
rences of superficial bladder cancer. BCG immunotherapy is not the 
gold standard for prophylaxis of superficial bladder cancer. However, 
it seems to be the agent of choice when treating carcinoma in situ.
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